Articles

Bioliberty's $3.3m Extension Sits on a 9.1m-Share A2 Re-cut

Bioliberty's $3.3m extension followed a 9.12m-share A2 re-cut, diluting the old base and authorising a separate Forward Health Ventures warrant.

By Hagen Hoferichter

Conduct your own private market research

Add dossaro to Claude or ChatGPT and run source-backed register research from your own workspace.

Bioliberty graphic showing 9.12m Series A2 shares added across 2026 and a separate Forward Health Ventures warrant authority

Bioliberty's public $3.3 million Series A extension is the last visible slice of a much larger cap-table change. Companies House filings show 9.12 million Series A2 shares added in three 2026 tranches, taking that preferred class to 47.3% of issued shares before the company disclosed four new hospital-backed investors. The register names Scottish National Investment Bank as the largest A2 holder in the last complete shareholder schedule and separately authorises a Forward Health Ventures warrant. It does not yet show which of the new strategic names received the final shares.

The public extension is smaller than the filing trail

Bioliberty announced the extension as €2.95 million, or $3.3 million, in November coverage. The announcement named TGH Ventures, Ballad Ventures, Whiterock and 25m Health as new institutional backers and took disclosed total funding to €12.07 million. Independent coverage repeats those terms, while the Scottish National Investment Bank's own account describes the preceding £6.2 million Series A, led by £3 million from SNIB, and a £1.5 million pre-Series A from the existing investor group.

The public story therefore sounds like a modest top-up for a rehabilitation company moving from clinical deployment toward home use and international expansion. The Companies House trail is more consequential. It shows a preferred Series A2 class being built in stages across 2026, rather than a single small allotment that can be mapped directly to the November announcement.

The distinction matters because a financing headline is not the same thing as a shareholder outcome. The filing history identifies the legal issuer, dates and share counts. It does not identify the new hospital-backed investors as the recipients of any particular tranche.

Evidence layerWhat the record establishesWhat remains open
Public extension€2.95m / $3.3m and four named new institutional backersWhich legal subscriber received which shares
SNIB account£7.7m over ten months, including a £6.2m Series A led by £3m from SNIBFinal close timing and final investor allocation
2026 SH01 filings9.12m Series A2 shares across three allotmentsValuation, preferences, voting and board rights
June CS01SNIB held 3,157,895 Series A2 shares before the late tranchesWhether that position changed after August and October
October resolutionA separate Forward Health Ventures warrant authorityWhether any warrant was exercised

The filing history for BIOLIBERTY LTD, company SC663888 is the public index for each of these documents.

A2 shares arrived in three tranches

The first relevant baseline is the 8 October 2025 allotment. Bioliberty issued 1,618,246 Series A shares at £0.93, taking total issued capital to 10,168,281 shares. That base comprised 8,550,035 ordinary shares and the 1,618,246 Series A shares.

On 24 March 2026, the company allotted 6,546,298 Series A2 shares at £0.95. At the filed price, that tranche represents £6,219,983.10 before any currency conversion. Issued capital rose to 16,714,579 shares.

The next allotment, dated 3 August and filed on 4 August, added 2,339,523 Series A2 shares at £0.95. The filed-price arithmetic is £2,222,546.85, and total issued shares rose to 19,054,102.

The 16 October allotment, filed on 19 October, added a further 234,899 Series A2 shares at £1.49. The form records non-cash consideration and a subscription price paid in US dollars. At the filed price, the tranche is £349,999.51, taking total issued capital to 19,289,001 shares.

Across those three allotments, 9,120,720 Series A2 shares were added. The earlier ordinary and Series A shares therefore account for 10,168,281 of 19,289,001 issued shares, or 52.7%. Series A2 accounts for 47.3%. That is an issued-share calculation. It is not a statement about founders' ownership, fully diluted options, liquidation proceeds or voting control.

The filed-price total of the three A2 tranches is about £8.79 million. It should not be presented as a one-to-one translation of the public $3.3 million extension. The public and filing timelines describe a broader staged financing sequence, and the October form includes non-cash consideration.

SNIB was the visible anchor before the last two tranches

The 10 June 2026 confirmation statement provides the last complete shareholder schedule in the reviewed evidence set before the August and October allotments. It lists Scottish National Investment Bank PLC with 3,157,895 Series A2 shares. That made SNIB the largest named A2 holder at that date, representing about 48.2% of the 6,546,298 A2 shares then outstanding and 18.9% of the 16,714,579 total issued shares.

The same schedule lists Hanna Capital SEZC, EOS and Archangels nominees, Old College Capital, MNL nominees for EOS Innovation Fund, Conduit EIS Impact Fund nominee and individual investors. Those names show a broad syndicate, but they do not turn the share schedule into a current post-extension cap table. In particular, the schedule predates the August and October tranches and does not assign the four newly announced hospital-backed investors to the late A2 shares.

SNIB's own account says its investment supports product development, manufacturing in Scotland and US expansion. Bioliberty is headquartered at the National Robotarium in Edinburgh, manufactures in Fife and opened a Boston headquarters in 2025. Those facts explain why the staged capital matters commercially: the company is funding both regulated rehabilitation technology and the costs of moving into more markets.

A warrant adds another layer of exposure

The 15 October 2026 member resolution, filed on 19 October, authorises up to 234,899 Series A2 shares and separately up to 227,272 Series A2 shares under warrant instruments with Forward Health Ventures A, LLC. The resolution also waives pre-emption rights.

That authority is not evidence that Forward Health Ventures exercised a warrant or received shares. It is evidence that the company created another route for a strategic or financing relationship alongside the issued A2 capital. The distinction is important in a young medtech company: an authorised warrant can affect future dilution, but it does not belong in the current shareholder denominator until exercised and filed.

This is where the story differs from a simple headline round. The public announcement names hospital-linked investors, the register shows a large preferred class and a separate warrant authority, and no single public document yet ties all three layers together.

What the register does not say

The filings do not disclose a post-October shareholder schedule. They do not reveal the valuation, liquidation preferences, conversion terms, board rights, option pool or the identity of the non-cash consideration recorded in the October allotment. They also do not prove that any founder sold shares or that a named hospital investor received a particular block.

The historical PSC record lists Shea Colman Quinn, Rowan Armstrong and Ross O'Hanlon as former 25% to 50% controllers, all ceased on 1 April 2022, with no current active PSC record in the reviewed set. That is source-native control evidence, not proof that no person has effective influence today. A company can have no active PSC filing while governance and economic rights remain distributed across preferred holders, directors and contractual arrangements.

The safest conclusion is therefore narrower than the financing headline. Bioliberty's old ordinary and Series A base was diluted by the issuance of 9.12m Series A2 shares. SNIB was a visible anchor before the final two tranches. Forward Health Ventures received an authorised warrant route, not a proved shareholding. The four new strategic names remain unassigned to the late shares until the next shareholder filing.

That evidence boundary is still commercially useful. It shows that the company is not simply adding a few investors to an unchanged cap table. It is financing a rehabilitation platform through a preferred-share structure whose final risk and control map has not yet been published.

The next CS01 should close the allocation gap

The decision-changing document is the next confirmation statement or shareholder schedule after the 19 October allotment. It should show whether TGH Ventures, Ballad Ventures, Whiterock and 25m Health appear as registered holders and whether SNIB's position changed after August and October. A later filing could also show exercise of the Forward Health Ventures warrant or clarify the October non-cash consideration.

Until then, the strongest defensible reading is the one the register supports: Bioliberty's $3.3 million extension sits at the end of a 9.1 million-share A2 re-cut that changed the issued-share denominator, while the investor-specific economics remain partly out of view. The Supa financing analysis offers a related example of why headline funding and disclosed equity should be kept separate.

Sources

Continue reading